Filter by Category: Medical Writing

Dalbavancin activity when tested against Streptococcus pneumoniae isolated in medical centers on six continents (2011-2014).

Dalbavancin activity when tested against Streptococcus pneumoniae isolated in medical centers on six continents (2011-2014). by Jones RN, Schuchert JE and Mendes RE. published in Antimicrob. Agents. Chemother. 2016; 60 (6): 3419-3425

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014).

Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). by Jones RN, Rhomberg PR and Mendes RE. published in Diag. Microbio. Infect. Dis. 2016; 86 (2): 249-251

Activity of fusidic acid tested against staphylococci isolated from patients in United States medical centers during 2014.

Activity of fusidic acid tested against staphylococci isolated from patients in United States medical centers during 2014. by Farrell DJ, Mendes RE, Castanheira M and Jones RN published in Antimicrob. Agents Chemother. 2016; 60 (6): 3827-3831

Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014

Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method.

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 379-381.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. by Ross JE, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (11): 7151-7152

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin.

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. by Mendes RE, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Clin. Microbiol. 2015; 53 (8): 2727-2730

Microbiological assessment of polymyxin B components tested alone and in combination.

Microbiological assessment of polymyxin B components tested alone and in combination. by Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (12): 7823-7825

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Global. Antimicrob. Res. 2015; 3: 161-165